JAGUAR HEALTH, INC. Business Combination, Consideration Transferred, Equity Interests Issued and Issuable
JAGUAR HEALTH, INC. (JAGX) reported Business Combination, Consideration Transferred, Equity Interests Issued and Issuable of $25.30 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-04-10.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable · last filed 2019-04-10
- JAGUAR HEALTH, INC. business combination, consideration transferred, equity interests issued and issuable for the quarter ending 2017-12-31 was $0.00.
- JAGUAR HEALTH, INC. business combination, consideration transferred, equity interests issued and issuable for fiscal 2017 was $25.30M.
| Period end | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 3 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 9 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month | Business Combination, Consideration Transferred, Equity Interests Issued and Issuable 12 month as first filed |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-10 | $25.30M 10-K · filed 2019-04-10 | $25.30M 10-K · filed 2018-04-09 | |
| 2017-09-30 | $25.30M 10-Q · filed 2018-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |